抗脂综合征:全面的临床审查
Vasileios Patriarcheas1, Georgios Tsamos2, Dimitra Vasdeki3
1First Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Stilponos Kyriakides 1 Str., 54636 Thessaloniki, Greece.
Journal of clinical medicine
|February 13, 2025
概括
抗脂综合征 (APS) 是一种罕见的自身免疫性疾病,导致血块和妊娠并发症. 早期诊断和多学科管理,包括了解2023年ACR/EULAR标准,是改善患者治疗结果的关键.
科学领域:
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 抗脂综合征 (APS) 是一种罕见的全身自身免疫性疾病.
- 它的特征是持久的抗脂抗体 (aPL),血栓形成和产科发病率.
- 对于其他自身免疫性疾病 (如狼) 可能是主要或次要的.
研究的目的:
- 为了总结目前对APS病原体的理解.
- 审查APS的诊断方法.
- 概述APS的治疗策略.
主要方法:
- 关于APS的综合文献综述.
- 专注于病理生理机制.
- 对诊断标准和治疗方法的分析.
主要成果:
- APS的发病过程涉及aPL,蛋白质和凝血的复杂相互作用.
- 除了血栓形成和产科问题之外,临床表现的广泛范围.
- 2023年ACR/EULAR标准有助于进一步进行APS调查.
结论:
- 早期诊断和多学科管理对于降低APS发病率至关重要.
- 我们鼓励大家熟悉2023年ACR/EULAR标准.
- 需要进一步的研究来优化APS治疗和理解机制.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Phosphoinositides and PIPs
8.3K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.3K
Chronic Pancreatitis II: Collaborative Care
60
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
60
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Clot Retraction and Fibrinolysis
3.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.5K
Disorders of Hemostasis
686
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
686


